Advanced calcium-blocking technology*1,2
Edwards SAPIEN 3 Ultra RESILIA transcatheter heart valve
Building on the benefits of the SAPIEN 3 platform
SAPIEN 3 Ultra valve, powered by RESILIA tissue technology
Three independently matched leaflets for thickness and elasticity
Potential to improve valve longevity and reduce reintervention*†1,2
The only transcatheter heart valve (THV) with dry tissue storage
*Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.2
†RESILIA tissue tested against tissue from commercially available bovine pericardial from Edwards Lifesciences in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg.
29 mm valve extends paravalvular leak (PVL) outer skirt technology to larger-annulus patients
Watch how RESILIA tissue technology works
See the clinical evidence behind RESILIA tissue
Read the latest clinical trial results for aortic valve replacement with RESILIA tissue
References
- Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149:340 -5.
- Beaver T, Bavaria JE, Griffith B, et al. Seven-year ourcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovac Surg. 2024 Sep;168(3):781-791.
Important safety information
Important safety information
Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-yearsin progress.2
Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the
Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-11582 v1.0